Trial reportThe international journal of tuberculosis and lung disease : the official journal of the International Union against Tuberculosis and Lung Disease2021
A partially randomised trial of pretomanid, moxifloxacin and pyrazinamide for pulmonary TB.
Open access · hybridAbstract readRandomized Controlled Trial
In one paragraph
Trial report in The international journal of tuberculosis and lung disease : the official journal of the International Union against Tuberculosis and Lung Disease, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 35 papers, 1 of them a synthesis that pooled it.
0numbers the graph read from it
0cells of the map it votes in
35citing papers in PubMed, 1 pooled it
2.8field-weighted citation impact, top 8% of its field
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
35 citing papers in PubMed, 1 synthesis or guideline pooled it, 62 citations in OpenAlex.
- A systematic review of endpoint definitions in late phase pulmonary tuberculosis therapeutic trials.Trials · 2021Pooled it
- Efficacy and safety of a 4-month quabodepistat, delamanid, and bedaquiline regimen for drug-susceptible pulmonary tuberculosis: a multicentre, open-label, randomised, proof-of-concept, non-inferiority, phase 2b/c trial.The Lancet. Infectious diseases · 2026Trial
- Efficacy and safety of 8-week regimens for the treatment of rifampicin-susceptible pulmonary tuberculosis (TRUNCATE-TB): a prespecified exploratory analysis of a multi-arm, multi-stage, open-label, randomised controlled trial.The Lancet. Infectious diseases · 2025Trial
- Bedaquiline, delamanid, linezolid, and clofazimine for rifampicin-resistant and fluoroquinolone-resistant tuberculosis (endTB-Q): an open-label, multicentre, stratified, non-inferiority, randomised, controlled, phase 3 trial.The Lancet. Respiratory medicine · 2025Trial
- Oral Regimens for Rifampin-Resistant, Fluoroquinolone-Susceptible Tuberculosis.The New England journal of medicine · 2025Trial
- Pyrazinamide Safety, Efficacy, and Dosing for Treating Drug-Susceptible Pulmonary Tuberculosis: A Phase 3, Randomized Controlled Clinical Trial.American journal of respiratory and critical care medicine · 2024Trial
- Prospectively predicting BPaMZ phase IIb/III trial outcomes using a translational mouse-to-human platform.Antimicrobial agents and chemotherapy · 2024Trial
- Assessing Pretomanid for Tuberculosis (APT), a Randomized Phase 2 Trial of Pretomanid-Containing Regimens for Drug-Sensitive Tuberculosis: 12-Week Results.American journal of respiratory and critical care medicine · 2023Trial
- Article
- Catalysing tuberculosis elimination in Indonesia: Health economic and policy insights from the BPaL regimen.PloS one · 2026Article
- Relapse and Emergent Resistance With Novel Short-Course Regimens for Multidrug-Resistant Tuberculosis, United States, 2022-2024.Open forum infectious diseases · 2026Article
- Rankings of tuberculosis antibiotic treatment regimens are sensitive to spatial scale, detection limit, and initial host bacterial burden.Journal of theoretical biology · 2025Article
- Article
- Operational considerations of select new treatment recommendations for drug-susceptible and drug-resistant tuberculosis.Journal of clinical tuberculosis and other mycobacterial diseases · 2025Review
- Hepatic safety of pretomanid- and pyrazinamide-containing regimens in TB Alliance clinical trials.IJTLD open · 2025Article
- Tuberculosis disease among people with HIV: therapeutic advances.The lancet. HIV · 2025Review
- Efficacy and safety data on pretomanid for drug-resistant TB.IJTLD open · 2025Review
- Analysis of time-to-positivity data in tuberculosis treatment studies: Identifying a new limit of quantification.International journal of antimicrobial agents · 2025Article
- Contribution of telacebec to novel drug regimens in a murine tuberculosis model.Antimicrobial agents and chemotherapy · 2025Article
- A Year in Review on Tuberculosis and Non-tuberculous Mycobacteria Disease: A 2025 Update for Clinicians and Scientists.Pathogens & immunity · 2025Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
39 authors at 20 institutions in 7 countries.
C D TweedMedical Research Council Clinical Trials Unit, University College London (UCL), London, UK.
G H WillsMedical Research Council Clinical Trials Unit, University College London (UCL), London, UK.
A M CrookMedical Research Council Clinical Trials Unit, University College London (UCL), London, UK.
E AmukoyeCentre for Respiratory Disease Research, Kenya Medical Research Institute (KEMRI), Kenyatta National Hospital, Nairobi, Kenya.
V BalanagLung Center of the Philippines, National Centre for Pulmonary Research, Quezon City, The Philippines.
A Y L BanPusat Perubatan Universiti Kebangsaan, Kuala Lumpur, Malaysia.
A L C BatesonCentre for Clinical Microbiology, UCL, London, UK.
M C BetteridgeGlobal Alliance for TB Drug Development, New York, NY, USA.
W BrumskineAurum Institute, Rustenburg, South Africa.
J CaoiliTropical Disease Foundation, Makati Medical Centre, Makati City, Phillippines.
R E ChaissonSchool of Medicine, Johns Hopkins University, Baltimore, MD, USA.
M CevikMedical School, University of St Andrews, St Andrews, UK.
F ConradieUniversity of the Witwatersrand, Clinical HIV Research Unit, Johannesburg.
R DawsonUniversity of Cape Town Lung Institute, Cape Town.
A Del ParigiGlobal Alliance for TB Drug Development, New York, NY, USA.
A DiaconTASK Applied Science, Bellville, South Africa & Division of Physiology, Department of Medical Biochemistry, University of Stellenbosch, Tygerberg, South Africa.
D E EverittGlobal Alliance for TB Drug Development, New York, NY, USA.
S M FabianeMedical Research Council Clinical Trials Unit, University College London (UCL), London, UK.
R HuntCentre for Clinical Microbiology, UCL, London, UK.
A I IsmailUniversiti Teknologi MARA, Selangor, Malaysia.
U LallooEnhancing Care Foundation, Durban International Clinical Research Site, Wentworth Hospital, Durban.
L LombardGlobal Alliance for TB Drug Development, New York, NY, USA.
C LouwMadibeng Centre for Research, Brits, & Department of Family Medicine, University of Pretoria, Pretoria.
M MalahlehaSetshaba Research Centre, Soshanguve, South Africa.
T D McHughCentre for Clinical Microbiology, UCL, London, UK.
C M MendelGlobal Alliance for TB Drug Development, New York, NY, USA.
F MhimbiraIfakara Health Institute (IHI), Dar es Salaam, Tanzania.
R N MoodliarTHINK (Tuberculosis and HIV Investigative Network), Durban, South Africa.
V NdubaKEMRI, Nairobi, Kenya.
A J NunnMedical Research Council Clinical Trials Unit, University College London (UCL), London, UK.
I SabiMbeya Medical Research Center, National Institute for Medical Research, Mbeya, Tanzania.
M A SebeThe Aurum Institute, Tembisa Clinical Research Centre, Tembisa.
R A P SelepeThe Aurum Institute, Klerksdorp, South Africa.
S StaplesTHINK (Tuberculosis and HIV Investigative Network), Durban, South Africa.
S SwindellsDepartment of Internal Medicine, University of Nebraska Medical Center, Omaha, NE, USA.
C H van NiekerkGlobal Alliance for TB Drug Development, Pretoria.
E VariavaKlerksdorp Tshepong Hospital, Klerksdorp, South Africa.
M SpigelmanGlobal Alliance for TB Drug Development, New York, NY, USA.
S H GillespieMedical School, University of St Andrews, St Andrews, UK.
TB Alliance · USUniversity College London · GBAurum Institute · ZAMRC Clinical Trials Unit at UCL · GBKenya Medical Research Institute · KEUniversity of St Andrews · GBIfakara Health Institute · TZJohns Hopkins University · USKalafong Hospital · ZALung Center of the Philippines · PHMakati Medical Center · PHMedical Research Council · GBNational Institute for Medical Research · TZSetshaba Research Centre · ZASouth African Tuberculosis Vaccine Initiative · ZAStellenbosch University · ZAUniversiti Teknologi MARA · MYUniversity Kebangsaan Malaysia Medical Centre · MYUniversity of Nebraska Medical Center · USUniversity of Pretoria · ZA
Funding
Leadership and Operations Center (LOC), AIDS Clinical Trials Group (ACTG); LOC 1/UM1AI068636 · NIAID · UNIV OF NORTH CAROLINA CHAPEL HILL · PI Joseph J Eron, RAJESH T GANDHI · 2011 to 2026
$1073.1MStatistical and Data Management Center (SDMC), AIDS Clinical Trials Group (ACTG)UM1AI068634 · NIAID · HARVARD UNIVERSITY D/B/A HARVARD SCHOOL OF PUBLIC HEALTH · PI Marlene Ann Cooper, Michael David Hughes · 2011 to 2026
$246.6MWits HIV Research Group CLINICAL TRIAL UNIT (CTU) reapplicationUM1AI069463 · NIAID · WITS HEALTH CONSORTIUM (PTY), LTD · PI REES, HELEN, SANNE, IAN MATTHIAS · 2012 to 2025
$31.8MAurum Clinical Trials UnitUM1AI154463 · NIAID · AURUM INSTITUTE NPC · PI Gavin John Churchyard · 2021 to 2026
$8.1MChief Scientist Office CAF/20/03Department of HealthMedical Research Council MC_UU_12023/27NIAID NIH HHS UM1 AI068634NIAID NIH HHS UM1 AI068636NIAID NIH HHS UM1 AI069463NIAID NIH HHS UM1 AI154463
Abstract
PubMed holds no abstract for this paper.
Indexed as
Antitubercular AgentsPyrazinamideTuberculosisDrug Therapy, CombinationHumansMoxifloxacinNitroimidazolesTreatment OutcomeAntitubercular AgentsMoxifloxacinNitroimidazolespretomanidPyrazinamide
Identifiers
What OpenQuestion holds
Textmetadata
LicenceCC BY
Read underepoch 390
Registered trials
None linked
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.